The Efficacy and Safety of S-ketamine in Elective Cesarean Section (ES-CS)
The Efficacy and Safety of S-ketamine in Elective Cesarean Section: a Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mingjun Xu
- Phone Number: 86-13701038959
- Email: snake650222@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA II;
- Parturients voluntarily sign an informed consent form, fully understands the purpose and significance of the study, and voluntarily abides by the clinical study procedure;
- Subjects who plan to be elected to undergo cesarean section under continuous combined spinal-epidural anesthesia;
- Age 18 to 40 years;
- The expected duration of surgery was less than 2h;
- Prenatal body mass index (BMI) was less than 35kg/m2。
Exclusion Criteria:
- Parturients with contraindications to continuous combined spinal-epidural anesthesia (such as history of central nervous system infection, spinal cord or spinal canal disease or surgery history, systemic infection, skin or soft tissue infection at the puncture site, coagulation dysfunction);
- Those who have a history of stroke, cognitive dysfunction, and epilepsy;
- Patients with a history of myocardial infarction, angina pectoris, or a serious arrhythmia such as second-degree and above-degree atrioventricular block within 6 months before screening;
- Pregnancy with other diseases (malignant tumors, hypertension during pregnancy, abnormal thyroid function, etc.);
- In the non-oxygen state, the peripheral blood oxygen saturation (SpO2) <92%;
- Subjects whose prolactin is greater than the upper limit of normal during the screening period;
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamine transferase (GGT)> 1.5 times than the normal value, and total bilirubin is higher than the upper limit of normal value, and blood creatinine (Cr)>1.2 times than the upper limit of normal value;
- The effect of combined spinal-epidural anesthesia is not good, and other anesthetics are needed;
- People with a history of allergies to various foods and drugs;
- Continuous taking for any reason within 3 months before the screening, including but not limited to: ketamine, non-steroidal anti-inflammatory drugs (aspirin, acetaminophen, indomethacin, diclofenac, ibuprofen, parecoxib) Sodium, etc.), alpha adrenergic receptor agonists (dexmedetomidine hydrochloride, clonidine, etc.), glucocorticoids (dexamethasone hydrochloride, hydrocortisone, methylprednisolone, etc.), antiepileptic ( Carbamazepine, sodium valproate, etc.), sedation (diazepam, estazolam, midazolam, alprazolam, barbital, phenobarbital and chloral hydrate, etc.), Chinese herbal medicine or Chinese patent medicine with pain and sedative effect;
- There is a history of drug abuse and/or alcohol abuse within 1 year before the screening;
- Participated in other drug or device trials within 3 months before the screening;
- Subjects judged by the investigator to be unsuitable to participate in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Saline group
Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊).
Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10~13mg 0.5% ropivacaine by a needle-through-needle technique.
When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score).
Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given.
Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation.
After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, "lock-out" interval of 10 min, last for 48 h postoperatively);
|
Saline group: pregnant women received saline, intravenous drip
Other Names:
|
|
Experimental: K1 group
Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊).
Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10~13mg 0.5% ropivacaine by a needle-through-needle technique.
When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score).
Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given.
Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation.
After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, "lock-out" interval of 10 min, last for 48 h postoperatively);
|
K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
Other Names:
K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
Other Names:
|
|
Experimental: K2 group
Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊).
Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10~13mg 0.5% ropivacaine by a needle-through-needle technique.
When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score).
Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given.
Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation.
After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, "lock-out" interval of 10 min, last for 48 h postoperatively);
|
K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
Other Names:
K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraoperative anesthesia effect
Time Frame: Day 1
|
Anesthesia effect is graded I-IV.
Level I means that it is very satisfactory, while Level IV means other anesthesia methods are needed to complete the operation.
We expect to reach level I.
|
Day 1
|
|
Ramsay Sedation Scale score
Time Frame: Day 1
|
The Ramsay Sedation Scale (RSS) was the first scale to be defined for sedated patients and was designed as a test of rousability.
The RSS scores sedation at six different levels, according to how rousable the patient is.
|
Day 1
|
|
Clock-in-the-Box(CIB)
Time Frame: Day 0 & Day 2
|
The Clock-in-the-Box (CIB) is a rapidly administered cognitive screening measure which has been previously validated with cognitive screening and neuropsychological assessments.
The CIB is scored on a 0-8 point scale and the total score includes two separate subscale scores.
The higher scores reflect better performance.
|
Day 0 & Day 2
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PHQ-9
Time Frame: Day 0 & Day 3 & Day 8 & Day 43
|
PHQ-9 is the major depressive disorder(MDD) module of the full PHQ.
Used to provisionally diagnose depression and grade severity of symptoms in general medical and mental health settings.
Scores each of the 9 DSM criteria of MDD as "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score.
Higher PHQ-9 scores are associated with decreased functional status and increased symptom-related difficulties, sick days, and healthcare utilization.
|
Day 0 & Day 3 & Day 8 & Day 43
|
|
Edinburgh Postnatal Depression Scale(EPDS)
Time Frame: Day 3 & Day 8 & Day 43
|
EPDS is a valuable and efficient way of identifying patients at risk for "perinatal" depression.
Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity depression.
|
Day 3 & Day 8 & Day 43
|
|
Apgar score
Time Frame: Day 0
|
The Apgar score is a test given to newborns soon after birth.
This test checks a baby's heart rate, muscle tone, and other signs to see if extra medical care or emergency care is needed.
The test is usually given twice: once at 1 minute after birth, and again at 5 minutes after birth.
|
Day 0
|
|
placental transfer of S-ketamine
Time Frame: Day 0
|
Placental transfer was evaluated based on the whole blood concentrations of S-ketamine in the maternal and cord blood
|
Day 0
|
|
blood gas
Time Frame: Day 0
|
Blood gases are a group of tests that are performed together to measure the pH and the amount of oxygen (O2) and carbon dioxide (CO2) present in a sample of blood
|
Day 0
|
|
umbilical arterial (UA)/umbilical venous (UV) ratio
Time Frame: Day 0
|
UA/UV ratio was evaluated based on the blood concentrations of S-ketamine in the umbilical arterial and umbilical venous blood
|
Day 0
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lei Wang, Beijing Haidian Maternal and Child Health Hospital
- Principal Investigator: Shaoqiang Huang, Obstetrics & Gynecology Hospital of Fudan University
- Principal Investigator: Jin Zhang, Fourth Hospital of Shijiazhuang City
- Principal Investigator: Yingbin Ren, Changzhi Maternal and Child Health Hospital
- Principal Investigator: Yong Qin, Linfen Maternity&Child Healthcare Hospital
- Principal Investigator: Shenghua Li, Maternal and Child Health Hospital, Jiading District
- Principal Investigator: Zhenhuan Hou, Tongzhou Maternal and Child Healthcare Hospital of Beijing
- Principal Investigator: Shuyi Miao, Beijing Chaoyang District Maternal and Child Health Care Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Depression
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Psychotropic Drugs
- Antidepressive Agents
- Ketamine
- Esketamine
Other Study ID Numbers
Other Study ID Numbers
- BeijingOGH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.